Lupin logo

LUPIN - Lupin News Story

₹1158.95 2.4  0.2%

Last Trade - 11:29am

Large Cap
Market Cap £5.13bn
Enterprise Value £5.21bn
Revenue £1.48bn
Position in Universe 85th / 3115

BUZZ-Indian drugmaker Lupin falls as March-qtr sales drop

Fri 14th May, 2021 7:07am
** Indian drugmaker's  LUPN.NS  shares fall as much as 3.8%
to 1,166 rupees, their biggest intraday pct. loss since April 12
    ** LUPN on Thursday reported
March-qtr consolidated sales fell 0.8% to 37.59 bln rupees
($512.31 mln)
    ** Co's North America sales fell 5.3%, while sales from
active pharmaceutical ingredients (API) segment were down 22.2%
- LUPN statement
    ** "Lupin missed our revenue and EBITDA estimates for the
quarter on subdued performance across most geographies. U.S. was
impacted by a weak flu season as expected and API segment was
hit by demand weakness" - Jefferies, which maintains "hold"
rating on stock
    ** Several brokerages downgrade rating
    ** LUPN Q4 net profit after taxes attributable to co's
owners rose to 4.60 bln rupees from 3.90 bln a yr earlier,
helped by 8.8% fall in total expenses and a near 50% fall in
total tax expense
    ** Up to Wednesday's close, stock had risen 24.1% YTD vs an
8.9% rise in the Nifty Pharma Index  .NIPHARM  

($1 = 73.3740 Indian rupees)

 (Reporting by Anuron Kumar Mitra in Bengaluru)
 ((; +91 99863 58469;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.